Effect of Perindopril Combined with Anlotinib in the Treatment of Locally Advanced and Metastatic Head and Neck Tumors
Objective:To investigate the efficacy and side effects of perindopril combined with anlotinib in the treatment of locally advanced and metastatic head and neck tumors. Methods:A total of 92 patients with head and neck cancer admitted to our hospital from October 2022 to June 2023 were randomly divided into routine group and combined group,with 46 patients in each group. The conventional group was treated with anlotinib monotherapy,and the combined group was treated with perindopril combined with anlotinib. The clinical efficacy,immune function and incidence of toxic and side effects were compared between the two groups. Results:The ORR and DCR in the combined group were higher than those in the conventional group (P<0.05). After treatment,CD4+and CD4+/CD8+in the two groups were lower than those in the same group before treatment,and those in the combined group were higher than the conventional group (P<0.05). There was no significant difference in the incidence of toxic and side effects between the two groups (P>0.05). Conclusion:Penpulimab combined with anlotinib has a good effect on patients with locally advanced and metastatic head and neck tumors,which is helpful to improve immune function and can provide reference for clinical treatment.
PenpulimabAnlotinibHead and neck tumorsCurative effectToxic and side reaction
万方数据
维普
